News coverage about Pulmatrix (NASDAQ:PULM) has trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm identifies positive and negative news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Pulmatrix earned a coverage optimism score of 0.21 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 46.1589893115581 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Shares of Pulmatrix (NASDAQ PULM) traded up $0.01 during trading hours on Friday, hitting $1.47. The company had a trading volume of 134,400 shares, compared to its average volume of 1,753,980. Pulmatrix has a 1 year low of $0.50 and a 1 year high of $6.98.

Pulmatrix (NASDAQ:PULM) last issued its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.08. The business had revenue of $0.34 million for the quarter. analysts predict that Pulmatrix will post -0.95 earnings per share for the current fiscal year.

Separately, Dawson James reissued a “buy” rating on shares of Pulmatrix in a research report on Wednesday, September 27th.

WARNING: “Pulmatrix (PULM) Receiving Somewhat Favorable Media Coverage, Report Finds” was first reported by Watch List News and is the property of of Watch List News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this news story can be read at https://www.watchlistnews.com/pulmatrix-pulm-receiving-somewhat-favorable-media-coverage-report-finds/1766323.html.

About Pulmatrix

Pulmatrix, Inc is a clinical stage biopharmaceutical company developing inhaled therapies to address serious pulmonary disease. The Company’s product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with lung disease, including cystic fibrosis.

Insider Buying and Selling by Quarter for Pulmatrix (NASDAQ:PULM)

Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with Analyst Ratings Network's FREE daily email newsletter.